patient 18 years old and more
with multiple sclerosis according to the criteria of Mac Donald 2010 : relapsing-remitting (RR), secondary-progressive (SP) or primary-progressive (PP)
for which treatment with dimethyl-fumarate has been prescribed
followed at the Rothschild Foundation in the Neurology Department
having given written consent to participation in the study

NCT02901106_inc_T1
Person
old
NCT02901106_inc_T2
Value
and more 18 years
NCT02901106_inc_T3
Condition
multiple sclerosis
NCT02901106_inc_T4
Measurement
criteria of Mac Donald 2010
NCT02901106_inc_T5
Qualifier
relapsing-remitting
NCT02901106_inc_T6
Qualifier
RR
NCT02901106_inc_T7
Qualifier
secondary-progressive
NCT02901106_inc_T8
Qualifier
SP
NCT02901106_inc_T9
Qualifier
primary-progressive
NCT02901106_inc_T10
Qualifier
PP
NCT02901106_inc_T11
Scope
relapsing-remitting (RR), secondary-progressive (SP) or primary-progressive (PP)
NCT02901106_inc_T12
Drug
dimethyl-fumarate
NCT02901106_inc_T13
Visit
Rothschild Foundation in the Neurology Department